← board
BNIGF
distress 0/10 · well-funded / low risk$0.010%today-37% from 52w high
Revenue
pre-revenue
Liquidity
$4M
Runway
—
Shares 1y
—
Price & events
+0.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
+0.0%
6M
+0.0%
1Y
-99.2%
2Y
-99.4%
5Y
-99.5%
All
Overview
- Volume
- 0
- 52 Week Range
- $0.01 – $0.01
- Float Shares
- 7.17M
- % Held by Insiders
- 73.93%
- % Held by Institutions
- 0.00%
- Beta
- -1.81
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.